The application for clinical acceptance of the new 3.1 antibiotic of Huabei Pharmaceutical Co., Ltd
-
Last Update: 2014-09-02
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The new cephalosporin complex is a macrolide antibiotic Its mechanism is novel, mainly through inhibiting RNA polymerase of bacteria, it can produce rapid anti infection (CDI) of Clostridium difficile Its treatment of CDI is better than the existing drugs The original manufacturer of fidamycin is optimer company In December 2010, FDA granted the drug the status of rare drug use and approved it to pass the fast track examination and approval On May 27, 2011, it was approved by FDA and the trade name is dificid CFDA shows that there is no approved production of fedamycin in domestic enterprises Before Huabei pharmaceutical, Haizheng Pharmaceutical (600267 SH) was the first domestic enterprise to declare the clinical application of the drug, which was accepted by CFDA on July 28 this year North China Pharmaceutical is the main antibiotic production base in China at present The total output of antibiotic API accounts for about 15% of the total output of the country, and the annual production capacity of powder injection is the first in the country
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
